Serum immunoglobulins on ibrutinib
| . | IgG . | IgA . | IgM . |
|---|---|---|---|
| Normal range, g/L | 7-16 | 0.91-5 | 0.4-2.3 |
| Patients | n = 35* | n = 43* | n = 34* |
| Median (IQR), g/L | |||
| Pretreatment | 7.07 (5.71-9.03) | 0.47 (0.36-1.23) | 0.31 (0.25-0.40) |
| 6 mo | 6.84 (5.40-8.98) | 0.74 (0.45-1.56) | 0.36 (0.30-0.46) |
| P = .10 | P < .0001 | P = .003 | |
| 12 mo | 6.62 (4.79-9.03) | 0.77 (0.50-1.63) | 0.34 (0.29-0.46) |
| P = .0006 | P < .0001 | P = .09 | |
| 24 mo | 5.87 (4.39-7.91) | 0.72 (0.52-1.71) | 0.26 (0.17-0.35) |
| P < .0001, n = 21† | P < .0001, n = 28† | P = .3, n = 23† |
| . | IgG . | IgA . | IgM . |
|---|---|---|---|
| Normal range, g/L | 7-16 | 0.91-5 | 0.4-2.3 |
| Patients | n = 35* | n = 43* | n = 34* |
| Median (IQR), g/L | |||
| Pretreatment | 7.07 (5.71-9.03) | 0.47 (0.36-1.23) | 0.31 (0.25-0.40) |
| 6 mo | 6.84 (5.40-8.98) | 0.74 (0.45-1.56) | 0.36 (0.30-0.46) |
| P = .10 | P < .0001 | P = .003 | |
| 12 mo | 6.62 (4.79-9.03) | 0.77 (0.50-1.63) | 0.34 (0.29-0.46) |
| P = .0006 | P < .0001 | P = .09 | |
| 24 mo | 5.87 (4.39-7.91) | 0.72 (0.52-1.71) | 0.26 (0.17-0.35) |
| P < .0001, n = 21† | P < .0001, n = 28† | P = .3, n = 23† |
All P values reflect paired comparisons to pretreatment samples.
Patients who received ≥12 months of ibrutinib. Only paired data are shown.
Patients who received ≥24 months of ibrutinib. Between 12 and 24 months, 3 patients discontinued treatment: 2 withdrew consent and 1 progressed with transformation. The remaining patients continued ibrutinib, but had not reached their 24-month follow-up at the time of analysis.